Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293616 | 1.00 | L3MBTL1 (0.41) | L3MBTL1RXFP1MEN1KMT2ANPC1 | |
| SCHEMBL1294189 | 0.89 | ALDH1A1 (0.34) | L3MBTL1MEN1KMT2ANPC1TDP1 | |
| SCHEMBL1294187 | 0.89 | ALDH1A1 (0.34) | L3MBTL1MEN1KMT2ANPC1TDP1 | |
| SCHEMBL10182417 | 0.88 | KMT2A (0.41) | L3MBTL1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL15773712 | 0.88 | KMT2A (0.41) | L3MBTL1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL15586735 | 0.88 | KMT2A (0.41) | L3MBTL1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL12752017 | 0.88 | KMT2A (0.41) | L3MBTL1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL10234338 | 0.85 | ALDH1A1 (0.41) | MEN1KMT2ANPC1TDP1ALDH1A1 | |
| SCHEMBL13046937 | 0.83 | NPC1 (0.38) | L3MBTL1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL754146 | 0.83 | NPC1 (0.38) | L3MBTL1MEN1KMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499127-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-11-12 | — | — | US | disclosed |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-07-16 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130317213-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | L3MBTL1 3648/4885RXFP1 4783/4885MEN1 4863/4885 |
| US-20130317213-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | L3MBTL1 1838/4885RXFP1 4645/4885MEN1 4870/4885 |
| US-20150322031-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | L3MBTL1 3763/4885RXFP1 4754/4885MEN1 4867/4885 |
| US-20150197499-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | L3MBTL1 3763/4885RXFP1 4754/4885MEN1 4867/4885 |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | L3MBTL1 1838/4885RXFP1 4645/4885MEN1 4870/4885 |
| US-20150322048-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | L3MBTL1 3763/4885RXFP1 4754/4885MEN1 4867/4885 |
| US-20130115193-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | L3MBTL1 3763/4885RXFP1 4754/4885MEN1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.